[ad_1] Granules India Ltd has received approval from the United States Food and Drug Administration (USFDA) for Lisdexamfetamine Dimesylate chewable tablets, used in the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Company Value Change %Change The pharmaceutical company, in an exchange filing on Tuesday, said its wholly-owned foreign subsidiary, Granules Pharmaceuticals, Inc. (GPI), has been […]
Granules India secures USFDA approval for antidepressant tablets – CNBC TV18
[ad_1] Granules Pharmaceuticals, Inc., a wholly-owned foreign subsidiary of Granules India, has achieved a significant milestone by securing approval from the U.S. Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) of Bupropion hydrochloride extended-release tablets USP (SR). The approved tablets are bioequivalent and therapeutically equivalent to GlaxoSmithKline LLC’s Wellbutrin SR sustained-release […]